In Depth 21 Nov 2024 Huntington’s disease: a therapeutic field on a bumpy ride For years, biotechs have been trying to develop medicines to cure the disease but much to no avail. Now, as clinical studies advance, there is hope. November 21, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 20 Nov 2024 Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024 The hypoparathyroidism treatment space has made quite a buzz this year with a major drug approval, acquisition, and significant advances in clinical trials. November 20, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 18 Nov 2024 What is Abcam’s founder, Jonathan Milner, up to? Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy. November 18, 2024 - 17 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 13 Nov 2024 Sleep apnea: biotechs snore points in the therapeutic space Therapeutic strides in biotech are proving to help address different stages of the sleep apnea. November 13, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 11 Nov 2024 Gene editing sector investment struggles: What’s driving the slowdown? Find out what is driving the slowdown in gene therapy investment, as the sector continues to struggle with widespread layoffs. November 11, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 7 Nov 2024 The biggest private biotech investments in October 2024 The companies Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics bagged the biggest private biotech investments in October 2024. November 7, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 6 Nov 2024 Tuberculosis research: Are we finally close to developing a more effective treatment option? Learn more about the positive advancements that have been made in tuberculosis research in an attempt to find new treatment options. November 6, 2024 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 5 Nov 2024 From consumer health to pure biopharma: Inside Sanofi’s strategic shift Delve into Sanofi’s “play to win” strategy as investments are ramping up after their consumer health division’s divestment. November 5, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 1 Nov 2024 Can AI cure Alzheimer’s disease? A couple of weeks back, we took a look at how artificial intelligence (AI) has had a transformative impact on cancer research. Today, we take a look at how AI tools help tackle another formidable challenge of modern biotech, Alzheimer’s disease. “Alzheimer’s is an incredibly complex disease with numerous factors at play. You have the […] November 1, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 30 Oct 2024 Spatial Transcriptomics: A window into disease The emerging spatial transcriptomics field is letting researchers map out gene expression in tumor and brain samples. How could this change the way we treat disease? October 30, 2024 - 11 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 30 Oct 2024 Could next-generation “switchable” CAR-T cells help improve the safety and efficacy of CAR-T therapies? Discover how next-generation “switchable” CAR-T cells could improve both the safety and efficacy of CAR-T therapies. October 30, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 25 Oct 2024 How biotech startups are trying to save the oceans with lab-grown fish Find out everything you need to know about lab-grown fish, including the startups trying to save the oceans with their products. October 25, 2024 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email